Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion Pharmaceutical TechnologyThoracic oncologists previously touted the potential of Bayer's Hyrnuo in HER2-mutant NSCLC in both the first- and second-line settings.OncologyRead full story pharminent September 10, 2026 (Last updated: September 10, 2026) Pharmaceutical Technology Thoracic oncologists previously touted the potential of Bayer’s Hyrnuo in HER2-mutant NSCLC in both the first- and second-line settings. Oncology Read full story Post navigation Previous: HHS appoints permanent FDA CBER, CDER headsNext: Bayer’s Hyrnuo Wins Accelerated Frontline Approval in HER2-Mutant NSCLC, Seven Months Behind Boehringer Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026